AP733A - Arylsulfonylamino hydroxamic acid derivatives. - Google Patents

Arylsulfonylamino hydroxamic acid derivatives. Download PDF

Info

Publication number
AP733A
AP733A APAP/P/1997/001078A AP9701078A AP733A AP 733 A AP733 A AP 733A AP 9701078 A AP9701078 A AP 9701078A AP 733 A AP733 A AP 733A
Authority
AP
ARIPO
Prior art keywords
alkyl
aryl
amino
methoxybenzenesulfonyl
heteroaryl
Prior art date
Application number
APAP/P/1997/001078A
Other versions
AP9701078A0 (en
Inventor
Todd Andrew Blumenkopf
Ralph Pelton Robinson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701078A0 publication Critical patent/AP9701078A0/en
Application granted granted Critical
Publication of AP733A publication Critical patent/AP733A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A compound of the formula wherein n, X, R3, R4 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloprdteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Description

ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES
Background of the Invention
The present invention relates to arylsulfonylamino hydroxamic acid derivatives which are inhibitors of matrix metalioproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (hereinafter
NSAID'S) and analgesics for the treatment of arthritis, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, in the treatment of cancer.
This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to pharmaceutical compositions useful therefor.
There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metailoproteases. Matrix-degrading metalioproteinases, such as gelatinase, stromelysin and collagenase, are involved in tissue matrix degradation (e.g. collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. comeal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Paget's disease and osteoporosis), tumor metastasis or invasion, as well as HIV-infection (J, Leuk. Biol.. 52 (2): 244-248, 1992).
Tumor necrosis factor is recognized to be involved in many infectious and autoimmune diseases (W. Fiers, FEBS Letters. 1991, 285. 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al., Clinical Immunology and Immunopathology. 1992, 62 S11).
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-2Summary of the Invention
The present invention relates to a compound of the formula
II
HO-N-CH (CH2>n
-N
R‘ \//‘ s\ oZ/\ or the pharmaceutically acceptable salts thereof, wherein n is 1 to 6;
X is OR1 wherein R1 is as defined below; azetidinyl, pyrrolidinyi, piperidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl or a bridged diazabicycloalkyl ring selected from the group consisting of
(CH2)p
AP/P/ 9 7 / 0 1 0 78
AP. 0 0 73 3
d e wherein r is 1, 2 or 3; m is 1 or 2; and p is 0 or 1;
wherein each heterocyclic group may optionally be substituted by one or two groups 15 selected from hydroxy, (C,-Ce)alkyl, (C^C^alkoxy, (C1-C10)a^l, (C^C^acyloxy, (C6C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl(CrC6)alkyl, (C5-Cg)heteroaryl (CrC6)alkyl, hydroxy (C1-Ce)alkyl, (C^CJalkoxy (C^-C^alkyl, (Cl-C6)acyloxy(C1-C6)alkyl, (Cr C6)alkylthio, (C.,-C6)alkylthio (C,-Ce)alkyl, (C6-C10)arylthio, (C6-C10) arylthio(C.,-C6)alkyl, R9R10N, R9R10NSO2i R9R10NCO, R’R10NCO(C,-Ce)alkyl wherein R9 and R10 are each independently hydrogen, (C^-C^alkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl (C,C6)alkyl or (C5-C9)heteroaryl (C^-CJalkyl or R9 and R10 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyi orthiomorpolinyl ring; R12SO2, R12SO2NH wherein R12 is trifluoromethyl, (C,C6)alkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (Cg-CJaryl^-C^aikyl or(C5-C9)heteroaryl (Cr
C6)alkyl; R13CONR9 wherein R9 is as defined above and R13 is hydrogen, (C1-C6)alkyl, (C^CeJalkoxy, (C6-C10)aryl, (C5-C9)heteroaryl, (CrCJaryKCrCJalkyliCg-C^aryKC,C6)alkoxy or (Cj-C^heteroaryKC^CeJalkyl; R14OOC, R^OOCiC^Cgjalkyl wherein R14 is (C^CJaikyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl (C,-C6)alkyl, 5-indanyl, CHR5OCOR6 wherein R5 is hydrogen or (C^CJalkyl and R6 is (C^CeJalkyl, (Cr
C6)alkoxy or (C6-C10)aryl; CH2CONR7R8 wherein R7 and R8 are each independently hydrogen or (C,-Ce)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyi or thiomorpholinyl
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-4ring; or R1SO (C.,CB)alkyl wherein R15 is H2N(CHR16)CO wherein R16 is the side chain of a natural D- or L-amino acid;
R1 is (C6-C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl(C1-C6)alkyl, 5-indanyl, CHR5OCOR6 or CH2CONR7R8 wherein Rs, R6, R7 and R8 are as defined above;
R3 and R4 are each independently selected from the group consisting of hydrogen, (C^C^alkyl, trifluoromethyl, trifluoromethyKC^C^alkyl, (C^-C^alkyl (difluoromethylene), (C1-C3)alkyl(difluoromethylene)(C1-C3)alkyl, (C6-C10)aryl, (C5C9)heteroaryl, (Cg-CJaryKC^-Cgjalkyl, (Cj-CgjheteroaryKC^Cgjalkyl, (C6-C10)aryl(C6C10)aryl, (C3-C6)cycloalkyl, (Cj-C^cycloalkyKC,C6)alkyl,hydroxy(C,-C6)alkyl, (C^-CJacyloxy^-C^alkyl, (C^^alkoxyiC^C^alkyl, (C,C10)acylamino(C,-C6)alkyl, piperidyl, (C^CJalkylpiperidyl, (Cg-C^JaryKC^CgJalkoxyiC,C6)alkyl, (Cg-CgjheteroaryKC^CJalkoxyCC^C^alkyl, (C^CgJalkylthioCC^CJalkyl, (C6C^arylthioCC^-CJalkyl, (C^C^alkylsulfinyKC^-CJalkyl, (Cg-C^JarylsulfinyKC^CgJalkyl, (C^CgJalkylsulfonyKC^Cgjalkyl, (Cg-C^JarylsulfonyKC^CgJalkyl, aminoiC^CgJalkyl, (C,CgJalkylaminoiC^Cgjalkyl, ((C1-C6)alkylamino)2(C1-C6)alkyl, R^COfC^-CgJalkyl wherein R17 is R14O or R7R8N wherein R7, R8 and R14 are as defined above; or R18(C,-Ce)alkyl wherein R18 is piperazinyl, (C^-C^acylpiperazinyl, (C6-C10)arylpiperazinyl, (C5C9)heteroarylpiperazinyl, (C,-C6)alkylpiperazinyl, (C6-C10)aryl(CrC6)alkylpiperazinyl, (C5CgJheteroaryKC^Cgjalkylpiperazinyl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperidyl, (C,-C6) alkylpiperid yl, (C6-C10)arylpiperidyl, (C5C9)heteroarylpiperidyl, (Cg-C^JaryKC^CgJalkylpiperidyl, (Cg-CJheteroarylfC,C6)alkylpiperidyl or (C,-C,0)acylpiperidyl;
or R3 and R4 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula
AP/P/ 9 7 / 0 1 0 7 8
hr
R21 wherein R21 is hydrogen, (C,-C10)acyl, (C^Cgjalkyl, (C6-C10)aryl(C,-C6)alkyl, (C5CgjheteroaryKC^Cgjalkyl or (C^Cgjalkylsulfonyl; and
AP.0 0 7 3 3
-5Q is (C^Csjalkyl, (C6-C10)aryl, (C6-C10)aryloxy(C6-C10)aryl, (C6-C10)aryl(C6C10)aryl, (Ce-C10)aryl(C6-Cw)aiyl(CrC6)alkyl, (C6-C10)aryioxy(C5-C9)heteroaryl, (C5C9)heteroaryl, (C,-C6)alkyl(C6-C10)aryl, (C^-CJalkoxyiCg-C^aryl, (C6-C10)aryl(Cr C6)alkoxy(C6-C10)aryl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, (Cs-C9)heteroaryloxy(Ce5 C10)aryl, (C^CJalkykCg-CJheteroaryl, (C^CgJalkoxyiCj-CJheteroaryl, (Cg-C^aryKC,C6)alkoxy(C5-C9)heteroaryl, (C5-C9)heteroaryloxy(C5-C9)heteroaryl, (C6-C1o)aryloxy(C1C6)alkyl, (Cg-CglheteroaryloxyiC^CJalkyl, (C1-C6)aIkyl(C6-C10)aryloxy(C6-C10)aryl, (Cr C6)alkyl(Cs-C9)heteroaryloxy(C6-C10)aryl, (C1-C6)alkyl(C6-C,0)aryloxy(C5-C9)heteroaryl, (C1-C6)alkoxy(C6-C10)aryloxy(C6-C10)aryl, (C^CJalkoxyiCg-CglheteroaryloxytCg-C^aryl or (C1-C6)alkoxy(C6-C10)aryloxy(C5-C9)heteroaryl wherein each aryl group is optionally substituted by fluoro, chloro, bromo, ((^-CJalkyl, (C^Cgjalkoxy or perfluoro^-Cgjalkyl;
with the proviso that X must be substituted when defined as azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl, (C,-C10)acylpiperazinyl, (C^CJalkylpiperazinyl, (C615 C10)arylpiperazinyl, (C5-Cg)heteroarylpiperazinyl ora bridged diazabicycloalkyl ring.
The term alkyl, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.
The term alkoxy, as used herein, includes O-alkyl groups wherein alkyl is defined above.
The term aryl, as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents selected from the group consisting of fluoro, chloro, trifiuoromethyl, (C,-C6)alkoxy, (C6-Cw)aryloxy, trifluoromethoxy, difluoromethoxy and (C^CJalkyl.
The term heteroaryl, as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyroyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents selected from the group consisting of fluoro, chloro, trifiuoromethyl, (C,-C6)alkoxy, (C6C10)aryloxy, trifluoromethoxy, difluoromethoxy and (C.,-C6)alkyl.
AP/P/ 9 7 / 0 1 0 78
AP . 0 0 7 3 3
-6The term acyl, as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy, aryl, arylalkyl or arylalkyloxy and the terms alkyl or aryl are as defined above.
The term acyloxy, as used herein, includes O-acyl groups wherein acyl is 5 defined above.
The term D- or L-amino acid, as used herein, unless otherwise indicated, includes glycine, alanine, valine, leucine, isoleucine, phenylalanine, asparagine, glutamine, tryptophan, proline, serine, threonine, tyrosine, hydroxyproline, cysteine, cystine, methionine, aspartic acid, glutamic acid, lysine, arginine or histidine.
The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.
Preferred compounds of formula I include those wherein n is 2.
Other preferred compounds of formula I include those wherein either R3 or R4 is not hydrogen.
Other preferred compounds of formula I include those wherein Ar is (C,C6)alkoxy(C6-C10)aryl,(C6-C10)aryl(C,-C6)alkoxy(C6-C10)aryl,4-fluorophenoxy(C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryl or (C^C^alkyKCg-C^jaryloxyiCg-C^jaryl.
Other preferred compounds of formula I include those wherein X is indolinyl or 20 piperidinyl.
More preferred compounds of formula I include those wherein n is 2; either R3 or R4 is not hydrogen; Ar is (C,-C6)alkoxy(C6-C10)aryl, (Ce-C^aryliC^-C^alkoxyiCeC10)aryl, 4-fluorophenoxy(C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryi or (C^CgjalkykCgC10)aryloxy(C6-C10)aryl; and X is indolinyl or piperidinyl.
Specific preferred compounds of formula I include the following:
3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionic acid indan-5-yl ester;
Acetic acid 1 -{3-[(1 -hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzenesulfonyl)-amino]propionyl}piperidin-4-yl ester;
2-Cyclohexyl-N-hydroxy-2-[[3-(4-hydroxypiperidin-1 -yl)-3-oxopropyl]-(4-methoxy-benzenesulfonyl)amino]acetamide;
Benzoic acid 1-{3-[(1-hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzenesulfonyl)amino]propionyl}piperidin-4-yl ester;
AP/P/ 9 7 / 0 1 0 78
AP.00733
-7N-Hydroxy-2-[[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
1- {3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid;
1-{3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester;
2- Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesuIfonyl)-[3-(4-methylaminopiperidin-1-yl)-3-oxopropyl]amino}acetamide;
3- (4-Chlorophenyl)-N-hydroxy-2-{(4-methoxybenzenesulfonyl)10 [3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}propionamide;
3- Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1-yl)-3-oxopropyl]amino}propionamide;
N-Hydroxy-2-[(3-[4-(2-hydroxy-2-methylpropyl)piperazin-1-yl]3-oxopropyl}-(4-methoxy-benzenesulfonyl)amino]-3-methylbutyramide;
2,2-Dimethylpropionic acid 2-(4-(3-((1-hydroxycarbamoyl-2-methylpropyl)-(4methoxy-benzenesulfonyl)amino]propionyl}piperazin-1 -yl)ethyI ester, and
Benzoic acid 2-(4-{3-[(1 -hydroxycarbamoyl-2-methylpropyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperazin-1 -yl)-ethyI ester.
Other specific compounds of formula I include the following;
2-Cy clohexyl-N-hyd roxy-2-[{3-[4-(2-hydroxy ethy I) pipe razin1-yl]-3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]acetamide;
N-Hydroxy-2-[(3-[5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1 ]hept-2-yl]-3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
2-((4-Benzy loxy benzen esulfonyl) -[3- (4-hydroxy pipe rid in-1 -yl)25 3-oxopropyl]amino}-N-hydroxy-3-methylbutyramide;
2-Cyclohexyl-2-([4-(4-fluorophenoxy)benzenesulfonyl]-(3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-amino}-N-hydroxyacetamide;
2-((4-(4-Butylphenoxy) benzenesulfony l]-[3-(4-hydroxypiperidin1-yl)-3-oxopropyl]-amino}-N-hydroxy-3-methylbutyramide;
1 -{(4-Methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}-cyclopentanecarboxylic acid hydroxyamide;
4- (3-(( 1-Hydroxy carbamoyl-2-methyl pro py I)-(4-m eth oxy benzenesulfonyl)amino]-propionyl}piperazine-2-carboxylic acid ethyl ester;
AP/P/ 9 7 / 0 1 0 78
ΑΡ ο 0 73 3
-83-[(Cyclo hexyl hydroxy carbarn oy I methyl)-(4-methoxy be nzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
3-[(1-Hydroxycarbamoylpentyl)-(4-methoxybenzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
3-[[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-2-methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester; and
3-[[4-(4-Fluorophenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-2methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester.
The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID’S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in such treatments and a pharmaceutically acceptable carrier.
The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, compounds of formula I may be used in combination with standard NSAID’S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition.
AP/P/ 97/01078
AP.00733
-9Detailed Description of the Invention
The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated n, R3, R4, X and Ar in the reaction Schemes and the discussion that follow are defined as above.
Scheme 1
AP/P/97 / 0 1 0 78
III
ΑΡ..0 0 7 3 3
-10Scheme 1 cont'd
AP/P/ 9 7 / 0 1 0 78
I
AP . 0 0 7 3 3
-11Scheme 2
viii
AP/P/ 97 / 0 1 0 78
IX iv
AP. j) Ο 7 3 3
-12Scheme 2 (continued)
IV
I
I
AP/P/ 97 / 0 1 0 78
I
AP.00733
-13ln reaction 1 of Scheme 1, the amino acid compound of formula VII, wherein R16 is (C.,-C6)alkyl, benzyl, allyl or tert-butyl, is converted to the corresponding compound of formula VI by reacting VII with a reactive functional derivative of an arylsulfonic acid compound, such as an arylsulfonyl chloride, in the presence of a base, such as triethylamine, and a polar solvent, such as tetrahydrofuran, dioxane, water or acetonitrile, preferably a mixture of dioxane and water. The reaction mixture is stirred, at room temperature, for a time period between about 10 minutes to about 24 hours, preferably about 60 minutes.
In reaction 2 of Scheme 1, the arylsulfonyl amino compound of formula VI, 10 wherein R16 is (C^CgJalkyl, benzyl, allyl or tert-butyl, is converted to the corresponding compound of formula V, wherein n is 1, 3, 4, 5 or 6, by reacting VI with a reactive derivative of an alcohol of the formula
O „ ll
R”-OC-(CHj)„-OH such as the chloride, bromide or iodide derivative, preferably the iodide derivative, wherein the R17 protecting group is (C^-C^alkyl, benzyl, allyl or tert-butyl, in the presence of a base such as potassium carbonate or sodium hydride, preferably sodium hydride, and a polar solvent, such as dimethylformamide. The reaction mixture is stirred, at room temperature, for a time period between about 60 minutes to about 48 hours, preferably about 18 hours. The R17 protecting group is chosen such that it may be selectively removed in the presence of and without loss of the R16 protecting group, therefore, R17 cannot be the same as R16. Removal of the R17 protecting group from the compound of formula V to give the corresponding carboxylic acid of formula IV, in reaction 3 of Scheme 1., is carried out under conditions appropriate for that particular R17 protecting group in use which will not affect the R16 protecting group. Such conditions include; (a) saponification where R17 is (C^Cgjalkyl and R16 is tert-butyl, (b) hydrogenolysis where R’7 is benzyl and R16 is tert-butyl or (C^CgJalkyl, (c) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid where R17 is tert30 butyl and R16 is (C,-C6)alkyl, benzyl or allyl, or (d) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R17 is allyl and R16 is (CrC6)alkyl, benzyl or tert-butyl.
In reaction 4 of Scheme 1, the carboxylic acid of formula IV is condensed with a compound of the formula HX or the salt thereof, wherein X is as defined above, to
AP/P/ 9 7 / 0 1 0 78
ΑΡ..0 ο 73 3
-14give the corresponding amide compound of formula III. The formation of amides from primary or secondary amines or ammonia and carboxylic acids is achieved by conversion of the carboxylic acid to an activated functional derivative which subsequently undergoes reaction with a primary or secondary amine or ammonia to form the amide. The activated functional derivative may be isolated prior to reaction with the primary or secondary amine or ammonia. Alternatively, the carboxylic acid may be treated with oxalyl chloride or thionyl chloride, neat or in an inert solvent, such as chloroform, at a temperature between about 25°C to about 80°C, preferably about 50°C, to give the corresponding acid chloride functional derivative. The inert solvent and any remaining oxalyl chloride or thionyl chloride is then removed by evaporation under vacuum. The remaining acid chloride functional derivative is then reacted with the primary or secondary amine or ammonia in an inert solvent, such as methylene chloride, to form the amide. The preferred method for the condensation of the carboxylic acid of formula IV with a compound of the formula HX, wherein X is as defined above, to provide the corresponding compound of formula III is the treatment of IV with (benzotriazol-l-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate in the presence of a base, such as triethylamine, to provide the benzotriazol-1-oxy ester in situ which, in turn, reacts with the compound of the formula HX, in an inert solvent, such as methylene chloride, at room temperature to give the compound of formula III.
Removal of the R16 protecting group from the compound of formula III to give the corresponding carboxylic acid of formula II, in reaction 5 of Scheme 1, is carried out under conditions appropriate for the particular R16 protecting group in use. Such conditions include; (a) saponification where R16 is lower alkyl, (b) hydrogenolysis where R16 is benzyl, (c) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid, where R16 is tert-butyl, or (d) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R16 is allyl.
In reaction 6 of Scheme 1, the carboxylic acid compound of formula II is converted to the hydroxamic acid compound of formula I by treating II with 1-(330 dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenztriazole in a polar solvent, such as dimethylformamide, followed by the addition of hydroxylamine to the reaction mixture after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxylamine is preferably generated in situ from a salt form, such
AP/P/ 9 7 / 0 1 0 78
AP .0 0 7 3 3
-15as hydroxylamine hydrochloride, in the presence of a base, such as Nmethylmorpholine. Alternatively, a protected derivative of hydroxylamine or its salt form, where the hydroxyl group is protected as a tert-butyl, benzyl, allyl or trimethylsilylether, may be used in the presence of (benzotriazol-1-yloxy)tris5 (dimethylamino) phosphonium hexafluorophosphate and a base, such as Nmethylmorpholine. Removal of the hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifiuoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride. The 2-trimethylsilylethyl ether may be removed by reaction with a strong acid, such as trifiuoroacetic acid or by reaction with a fluoride source such as boron trifluoride etherate. N.O-bis(4-methoxybenzyl)hydroxylamine may also be used as the protected hydroxylamine derivative where deprotection is achieved using a mixture of methanesulfonic acid and trifiuoroacetic acid.
In reaction 1 of Scheme 2, the arylsulfonylamino compound of formula VI, wherein R16 is (C,-Ce)alkyl, benzyl or tert-butyl, is converted to the corresponding compound of formula VIII by reacting VI with a reactive functional derivative, such as the halide, preferably the iodide derivative, of 3-(tert-butyldimethyIsilyloxy)-1 -propanol in the presence of a base, such as sodium hydride. The reaction is stirred in a polar solvent, such as dimethylformamide, at room temperature, for a time period between about 2 hours to about 48 hours, preferably about 18 hours.
In reaction 2 of Scheme 2, the compound of formula VIII is converted to the alcohol compound of formula IX by treatment of VIII with an excess of an acid, such as acetic acid, or an excess of a Lewis acid, such as boron trifluoride etherate. When using an acid, such as acetic acid, water is added and a water-soluble cosolvent, such as tetrahydrofuran, can be added to promote solubility. The reaction is stirred for a time period between about 18 hours to about 72 hours, preferably about 24 hours, at a temperature between about room temperature to about 60°C, preferably about 50°C. When using a Lewis acid, such as boron trifluoride etherate, the reaction is stirred in a solvent, such as methylene chloride, for a time period between about 10 minutes to about 6 hours, preferably about 20 minutes, at a temperature between about -20°C to about room temperature, preferably about room temperature.
AP/P/ 9 7 / 0 1 0 78
AP.D 0 7 3 3
-16ln reaction 3 of Scheme 2, the alcohol compound of formula IX is oxidized to the carboxylic acid compound of formula IV, wherein n is 2, by reacting IX with an excess of sodium periodate and a catalytic amount of ruthenium trichloride in a solvent mixture consisting of acetonitrile, water and carbon tetrachloride, at room temperature, for a time period between about 1 hour to about 24 hours, preferably about 4 hours.
The compound of formula IV, wherein n is 2, is further reacted to provide the hydroxamic acid compound of formula I, wherein n is 2, according to the procedure described above in reactions 4, 5 and 6 of Scheme 1.
Pharmaceutically acceptable salts of the acidic compounds of the invention are 10 salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris(hydroxymethyl)-methylammonium slats.
Similarly acid addition salts, such as of mineral acids, organic carboxylic and 15 organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.
The ability of the compounds of formula I or their pharmaceutically acceptable salts (hereinafter also referred to as the compounds of the present invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following in vitro assay tests.
Biological Assay
Inhibition of Human Collaqenase (MMP-1)
Human recombinant collagenase is activated with trypsin using the following ratio: 10 pg trypsin per 100 pg of collagenase. The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 //g/10 /zg trypsin) of soybean trypsin inhibitor is added.
mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme:
mM-> 120 pM-> 12 μΜ-> 1.2 μΜ-> 0.12 μΜ
Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-17be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.
Collagenase is diluted to 400 ng/ml and 25 μΙ is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/ml.
Substrate (DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 μΜ in assay buffer. The assay is initiated by the addition of 50 μΙ substrate per well of the microfluor plate to give a final concentration of 10 μΜ.
Fluorescence readings (360 nM excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours.
Fluorescence vs time is then plotted for both the blank and collagenase 15 containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine ICM values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100). IC^’s are determined from the concentration of inhibitor that gives a signal that is 50% of the control.
If ICjo’s are reported to be <0.03 μΜ then the inhibitors are assayed at concentrations of 0.3 μΜ, 0.03 μΜ, 0.03 μΜ and 0.003 μΜ.
Inhibition of Gelatinase (MMP-2)
Inhibition of gelatinase activity is assayed using the Dnp-Pro-Cha-Gly-Cys(Me)His-Ala-Lys(NMA)-NH2 substrate (10 μΜ) under the same conditions as inhibition of human collagenase (MMP-1).
72kD gelatinase is activated with 1 mM ΑΡΜΑ (p-aminophenyl mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give final concentrations in the assay of 30 μΜ, 3 μΜ, 0.3 μΜ and 0.03 μΜ. Each concentration is done in triplicate.
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-18Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours.
ICgo's are determined as per inhibition of human coliagenase (MMP-1). If IC^s are reported to be less than 0.03 μΜ, then the inhibitors are assayed at final concentrations of 0.3 μΜ, 0.03 pM, 0.003 μΜ and 0.003 μΜ.
Inhibition of Stromelvsin Activity (MMP-3)
Inhibition of stromelysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., Spectrophotometric Assay for Vertebrate Coliagenase, Anal. Biochem. 147, 437-440 (1985)). Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-GlySCH[CH2CH(CH3)2]CO-Leu-Gly-OC2H5] yields a mercaptan fragment that can be monitored in the presence of Ellman’s reagent.
Human recombinant prostromelysin is activated with trypsin using a ratio of 1 μϊ of a 10 mg/ml trypsin stock per 26 μg of stromelysin. The trypsin and stromelysin are incubated at 37°C for 15 minutes followed by 10 μΙ of 10 mg/ml soybean trypsin inhibitor for 10 minutes at 37°C for 10 minutes at 37°C to quench trypsin activity.
Assays are conducted in a total volume of 250 μϊ of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter plates. Activated stromelysin is diluted in assay buffer to 25 pg/ml. Ellman’s reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 μϊ per well yielding at 1 mM final concentration.
mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 μϊ- to the appropriate wells yields final concentrations of 3 μΜ, 0.3 μΜ, 0.003 μΜ, and 0.0003 μΜ. All conditions are completed in triplicate.
A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 μϊ to each well to give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman’s reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader.
IC50 values were determined in the same manner as for coliagenase.
AP/P/ 97 / 0 1 0 78
AP. Ο Ο 7 3 3
-19Inhibition of MMP-13
Human recombinant MMP-13 is activated with 2mM ΑΡΜΑ (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5mM calcium chloride, 20/zM zinc chloride,
0.02% brij). Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.
mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 μΜ, 3pM, 0.3 pM, and 0.03 μΜ.
Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) is prepared asfor inhibition of human collagenase (MMP-1) and 50 μ\ is added to each well to give a final assay concentration of 10 μΜ. Fluorescence readings (360 nM excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour.
Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.
ICgo’s are determined as per inhibition of human collagenase (MMP-1). If IC^'s are reported to be less than 0.03 μΜ, inhibitors are then assayed at final concentrations of 0.3 μΜ, 0.03 pM, 0.003 pM and 0.0003 μΜ.
Inhibition of TNF Production
The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following in vitro assay:
Human mononuclear cells were isolated from anti-coagulated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2 x 106 /ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations.
AP/P/ 9 7 / 0 1 0 78
AP ._ Ο Ο 7 3 3
-20180/y of the cell suspension was aliquoted into flate bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 200//1. All conditions were performed in triplicate. After a four hour incubation at 37°C in an humidified CO2 incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supernatants removed and assayed for TNFa using the R&D ELISA Kit.
For administration to mammals, including humans, for the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF), a variety of conventional routes may be used including orally, parenterally and topically. In general, the active compound will be administered orally or parenteral'y at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
The compounds of the present invention can be administered in a wide variety of different dosage forms, in genera!, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia.
Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules: preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. In the case of animals, they are
AP/P/ 97/01078
AP.Λ Ο 7 3 3
-21advantageously contained in an animal feed or drinking water in a concentration of 55000 ppm, preferably 25 to 500 ppm.
For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared.
Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to
3 divided doses.
The present invention is illustrated by the following examples, but it is not limited to the details thereof.
EXAMPLE 1
2-Cyclohexvl-N-hydroxv-2-((4-methoxvbenzenesulfonvO-r3-(4-methvl-aminopipe ridin-1-vD-3-oxopropvnamino)acetamide (A) To a solution of D-cyclohexylgycine benzyl ester hydrochloride (17.0 grams,
59.9 mmol) and triethylamine (17.6 mL, 126.3 mmol) in water (60 mL) and 1,4-dioxane (100 mL) was added 4-methoxybenzenesulfonyl chloride (13.0 grams, 62.9 mmol). The mixture was stirred at room temperature for 16 hours and then most of the solvent was removed by evaporation under vacuum. The mixture was diluted with ethyl acetate and was washed successively with dilute hydrochloric acid solution, water, saturated sodium bicarbonate solution, and brine. The organic solution was dried over magnesium sulfate and concentrated to leave N-(4-methoxybenzenesulfonyl)-D-cyclohexylglycine benzyl ester as a white solid, 24.51 grams (99%).
(B) N-(4-Methoxybenzenesulfonyl)-D-cyclohexylglycine benzyl ester (12.0 grams,
29.16 mmol) was added to a suspension of sodium hydride (0.78 grams, 32.5 mmol) in dry Ν,Ν-dimethylformamide (100 ml) and, after 20 minutes, tert-butyl-(3-iodopropoxy)-dimethylsilane(9.2 grams, 30.6 mmol) was added. The
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-22resulting mixture was stirred at room temperature for 16 hours and was then quenched by addition of saturated ammonium chloride solution. The Ν,Ν-dimethylformamide was then removed by evaporation under vacuum. The residue was taken up in diethyl ether and washed successively with dilute hydrochloric acid solution, water and brine. After drying over magnesium sulfate, the diethyl ether was evaporated under vacuum to afford a yellow oil from which [[3-(tert-butyldimethylsilanyloxy)propyl](4-methoxybenzenesulfonyl)-amino]cyclohexylacetic acid benzyl ester, a clear oil (13.67 grams, 79%), was isolated by flash chromatography on silica gel eluting with 10% ethyl acetate in hexane.
(C) To a solution of [[3-(tert-butyldimethylsilanyloxy)propyl](4-methoxybenzenesulfonyl)amino]cyclohexylacetic acid benzyl ester (13.67 grams, 23.2 mmol) in methylene chloride (60 mL) at room temperature was added boron trifluoride etherate (21 mL, 171 mmol). After 20 minutes, the reaction was quenched by addition of saturated ammonium chloride solution and subsequent addition of ethyl acetate and water. The organic phase was separated, washed with brine and dried over magnesium sulfate. Evaporation of the solvent under vacuum gave an oil from which cyclohexyl[(3-hydroxypropyl)(4-methoxy-benzenesulfonyl)amino]acetic acid benzyl ester, a clear oil (11.25 grams, 100%), was isolated by flash chromatography on silica gel eluting with 20% ethyl acetate in hexane and then 40% ethyl acetate in hexane.
(D) Cyclohexyl[(3-hydroxypropyl)(4-methoxybenzenesulfonyl)amino]acetic acid benzyl ester (45.8 grams, 96 mmol) and sodium periodate (92.6 grams, 433 mmol) were dissolved in a mixture of acetonitrile (345 mL), carbon tetrachloride (345 mL) and water (460 mL). While cooling in an ice bath, ruthenium trichloride monohydrate (4.4 grams, 21 mmol) was then added. The resulting mixture was mechanically stirred with ice bath cooling for 30 minutes. The bath was removed and stirring was continued at room temperature for 4 hours. The reaction mixture was diluted with ethyl acetate and filtered through diatomaceous earth. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine. After drying over magnesium sulfate, the solvents were evaporated to give a dark oil from which 3-[(benzyloxycarbonylcyclohexylmethyl)(4-methoxybenzenesulfonyl)amino]propionic acid, a white foam (28.1 grams, 60%), was isolated by flash chromatography on silica gel eluting sequentially with chloroform and
1% methanol in chloroform.
AP/P/ 9 7 / 0 1 0 78
AP.-0 0 73 J
-23(Ε) To a solution of 3-[(benzyloxycarbonylcyclohexylmethyl)(4-methoxybenzenesulfonyl)-amino]propionic acid (1.57 grams, 3.21 mmol) in methylene chloride (45 mL) were added sequentially triethylamine (1.12 mL, 8.04 mmol), methylpiperidin-4-ylcarbamic acid tert-butyl ester (0.89 grams, 4.15 mmol) , and (benzotriazol-1 -yloxy)tris(dimethylamino)-phosphonium hexafluoroborate (1.56 grams, 3.53 mmol). The resulting mixture was stirred for 16 hours at room temperature and then diluted with methylene chloride. The solution was washed successively with 0.5 M hydrochloric acid solution, saturated sodium bicarbonate solution and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 50% ethyl acetate in hexane to afford [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]-3-oxopropyl}(4-methoxybenzen esulfonyl)amino]cyclohexylacetic acid benzyl ester as an oil (1.89 grams, 86%).
(F) To a solution of [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]3-oxopropyl}(4-methoxybenzenesulfonyl)amino]cyclohexylacetic acid benzylester(1.89 grams, 2.76 mmol) in ethanol (90 mL) was added 10% palladium on activated carbon (0.32 grams). The mixture was agitated under 3 atmospheres hydrogen in a Parr shaker for 2 hours. The catalyst was removed by filtration through nylon (pore size 0.45 pm) and the solvent was evaporated leaving [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]-3-oxo-propyl}(4-methoxybenzenesulfonyl)amino]cyclohexylacetic acid as a white foam (1.65 grams, 100%).
(G) To a solution of [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]3-oxopropyl}(4-methoxybenzenesulfonyl)amino]cyclohexyiacetic acid(1,65grams, 2.76 mmol) in methylene chloride (30 mL) were added sequentially O-benzylhydroxylamine hydrochloride (0.47 grams, 2.94 mmol), triethylamine (1.25 mL, 9.0 mmol) and (benzotriazol-1 -yloxy)tris(dimethylamino)phosphonium hexafluoroborate (1.36 grams, 3.07 mmol). The resulting mixture was stirred for 24 hours at room temperature and then concentrated in vacuo. The residue was taken up in ethyl acetate and washed successively with 0.5 M hydrochloric acid solution, water, saturated sodium bicarbonate solution and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 40% hexane in ethyl acetate to afford (1-{3-[(benzyloxycarbamoylcyclohexylmethyl)(4-methoxybenzenesulfonyl)amino]-propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl esteras a clear oil (1.86 grams, 96%).
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-24(H) To a solution of (1-{3-[(benzyloxycarbamoylcyclohexylmethyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester (1.86 grams, 2.65 mmol) in methanol (80 mL) was added 5% palladium on barium sulfate (0.85 grams). The mixture was agitated under 3 atmospheres hydrogen in a
Parr shaker for 2.5 hours. The catalyst was removed by filtration through nylon (pore size 0.45 pm) and the solvent was evaporated leaving (1-{3-[(cyclohexylhydroxycarbamoylmethyl)(4-methoxybenzene-sulfonyl)amino]propio nyl}piperidin-4-yl)methylcarbamic acid tert-butyl esteras a white foam (1.53 grams, 95%).
The title compounds of examples 2-8 were prepared analogously to that described in Example 1 using D-valine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 2
Acetic acid 1 -hvdroxycarbamovl-2-methvlpropvl)(4-methoxybenzenesulfonyl)-amino1propionvl)piperidin-4-vl ester Coupled with acetic acid piperidin-4-yl ester. MS: 500 (M+1).
EXAMPLE 3
Butyric acid 1-(3-Π1-hvdroxvcarbamovl-2-methyipropyi)-(4methoxv-benzenesulfonvl)-amino1propionyl)piperidin-4-vl ester
Coupled with butyric acid piperidin-4-yl ester. MS: 528 (M+1).
EXAMPLE 4
Benzoic acid 1-{3-H1-hvdroxvcarbamovi-2-methvlpropvlK4-methoxv-benzene25 sulfonvl)amino1propionyl)piperidin-4-vl ester
Coupled with benzoic acid piperidin-4-yl ester. MS: 562 (M+1). Analysis Calculated for C27H35N3O8S*1.75 H2O: C, 54.67; H, 6.54; N, 7.08. Found: C, 54.52, H, 6.14; N, 7.85.
Example 5
N-Hvdroxv-2-rr3-(4-hvdroxvpiperidin-1-vl)-3-oxopropvn-(4-methoxy-benzenesulfonvl)amino1-3-methylbutvramide
Coupled with 4-hydroxypiperidine. MS: 458 (M+1). Analysis calculated for C20H31N3O7S*H2O: C, 50.51; H, 6.99; N, 8.84. Found: C, 50.04; H, 6.84; N, 9.14.
AP/P/ 9 7 / 0 1 0 78
AP.00733
-25EXAMPLE 6 (1-<3-ni-Hvdroxvcarbamovl-2-methylpropvl)(4-methoxvbenzenesulfonvn-amino1
-propionvl)piperidin-4-vl)-methylcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester.
EXAMPLE 7
1-(3-r(1-Hvdroxvcarbamovl-2-methvlpropylH4-methoxvbenzenesulfonvl)-amino1· propionvDpiperidine-4-carboxylic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 513 (M+1).
EXAMPLE 8 (4-{3-r(1-Hvdroxvcarbamovl-2-methylpropvl)(4-nriethoxvbenzenesulfonvl)-amino1propionvOpiperazin-l-vD-acetic acid ethyl ester
Coupled with piperazin-1-ylacetic acid ethyl ester. HRMS calculated for C23H37N4O8S(M+1): 529.2332. Found: 529.2366.
The title compounds of Examples 9-10 were prepared analogously to that described in Example 1 using D-leucine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 9 (1-{3-rf1-Hydroxvcarbamovi-3-methylbutyl)(4-methoxvbenzenesulfonvl)-aminolpropionv0piperidin-4-vl)methylcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 585 (M+1).
EXAMPLE 10
1-(3-Γ(1-Hydroxy carbamovl-3-methylbutvl)-(4-methoxvbenzenesulfonvl)-amino125 propionvl}piperidine-4-carboxylic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. Melting pont 78-80°C. MS: 528 (M+1).
The title compounds of Examples 11-13 were prepared analogously to that described in Example 1 using D-norleucine benzyl ester as the starting material in step A and the indicated amine or alcohol in step E.
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-26EXAMPLE11 (1-i3-r(1-Hvdroxvcarbamovlpentvil(4-methoxvbenzenesulfonvl)amino1propionvDpiperidin-4-vl)methvlcarbamic acid tert-butyl ester Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester.
EXAMPLE 12
1-f3-i(1-Hvdroxvcarbamoylpentvl)(4-methoxvbenzenesulfonyl)amino1propionvnpiperidine-4-carboxylic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 528 (M+1).
EXAMPLE 13
3-r(1-Hvdroxvcarbamovlpentvl)(4-methoxvbenzenesulfonvl)aminol-propionicacid indan-5-vl ester
Coupled with 5-indanol. MS: 505 (M+1).
The title compounds of Examples 14-15 were prepared analogously to that 15 described in Example 1 using D-tert-butylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 14 (1-f3-r(1-Hvdroxvcarbamovl-3.3-dimethvlbutvl)-(4-methoxvbenzene-sulfonvD20 aminolpropionvl)piperidin-4-vl)methylcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 599 (M+1).
EXAMPLE 15
1-{3-r(1-Hvdroxvcarbamovl-3.3-dimethylbutvl)(4-methoxv-benzenesulfonyl)aminolpropionyl}piperidine-4-carboxvlic acid ethyl ester 25 Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 542 (M+1).
The title compounds of Examples 16-18 were prepared analogously to that described in Example 1 using D-cyclohexylglycine benzyl ester as the starting material in step A and the indicated amine or alcohol in step E.
AP/P/ 97 / 0 1 0 78
ΉΡ . 407 3 3
-27EXAMPLE 16
2- Cvclohexvl-N-hvdroxv-2-rr3-(4-hvdroxvpiperidin-1-yl)-3-oxopropvn-(4methoxy-benzenesulfonvDaminolacetamide
Coupled with 4-hydroxypiperidine. MS: 498 (M+1). Analysis calculated for 5 C23H35N3O7S*0.5H2O: C, 54.53; H, 7.16; N, 8.29. Found: C, 54.21; H, 6.98; N, 8.21.
EXAMPLE 17
1-f3-nCvciohexvlhvdroxvcarbamovlmethvl)(4-methoxvbenzenesulfonyl)-aminoT propionvl)piperidine-4-carboxvlic acid ethyi ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 554 (M+1). Analysis 10 calculated for C26H39N3O8S»0.5H2O: C, 55.59; H, 7.16; N, 7.47. Found: C, 55.53; H,
7.18; N, 7.57.
EXAMPLE 18
3- f(Cvclohexvlhvdroxvcarbamovlmethvl)-(4-methoxvbenzenesulfonvl)-amino1propionic acid indan-5-vl ester
Coupled with 5-indanol. MS: 531 (M+1). Analysis calculated for C27H34N2O7S*H2O: C, 59.11; H, 6.61; N, 5.10. Found: C, 59.40; H, 6.17; N, 5.06.
The title compounds of Examples 19-20 were prepared analogously to that described in Example 1 using D-phenylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 19 (l-f3-f(l-Hvdroxvcarbamovl-2-Dhenvlethvl)(4-methoxvbenzenesuIfonvl)-amino1propionvl)piperidin-4-vl)methvlcarbamic acid tert-butyl ester 25 Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 619 (M+1).
EXAMPLE 20 l-(3-Kl-Hvdroxvcarbamovl-2-phenvlethvl)-(4-methoxvbenzenesulfonvl)-aminoL· propionvnpiperidine-4-carboxvlic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 561 (M+1).
AP/P/ 9 7 / 0 1 0 78
AP.0 0 733
-28The title compounds of Examples 21-22 were prepared analogously to that described in Example 1 using D-4-fluorophenylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 21 (l-f3-[f2-(4-Fluorophenvl)-l-hvdroxvcarbamovlethvn-(4-methoxv-benzenesulfonvl)aminolpropionyl)piperidin-4-yl)methylcarbamic acid tert-butyl ester
Coupled with methyI-piperidin-4-ylcarbamic acid tert-butyl ester.
EXAMPLE 22 l-{3-if2-(4-FluoronhenvO-l-hydroxycarbamoylethvll(4-methoxy-benzenesulfonvD aminolpropionvllpiperidine-4-carboxyIic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 580 (M+l). Analysis calculated for C27H34FN3O8S: C, 55.95; H, 5.91; N, 7.25. Found: C, 55.72; H, 5.79; N, 7.08.
The title compounds of Examples 23-24 were prepared analogously to that described in Example 1 using D-4-homophenylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 23 (l-i3-Kl-Hvdroxvcarbamoyl-3-phenvlpropvl)-(4-methoxvbenzene-sulfonyl)aminolpropionyl) niperidin-4-vI)methylcarbamic acid tert-butyl ester Coupled with tert-butyl ester using methyI-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 633 (M+l).
EXAMPLE 24 l-(3-f(l-HvdroxvcarbamovI-3-phenylpropvh-(4-methoxvbenzene-sulfonvl)aminolpropionyllpiperidine-4-carboxylic acid ethyl ester
AP/P/ 97 / 0 1 0 78
Coupled with piperidine-4-carboxyIic acid ethyl ester. MS: 576 (M+l).
AP.00733
-29The title compounds of Examples 27-28 were prepared analogously to that described in Example 1 using D-O-tert-butylserine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 25 (l-(3-f(2-tert-Butoxv-l-hydroxvcarbamoylethvl)(4-methoxybenzene-sulfonvl)aminolpropionvl)piperidin-4-vI)methvlcarbamic acid tert-butyl ester Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 615 (M+l).
EXAMPLE 26 l-(3-[(2-tert-Butoxv-l-hvdroxvcarbamovlethvl)(4-methoxy-benzenesiilfonvDaminolpropionvllpiperidine-4-carboxylic acid ethyl ester Coupled with piperidine-4-carboxyIic acid ethyl ester. MS: 558 (M+l).
The title compounds of Examples 27-28 were prepared analogously to that 15 described in Example 1 using D-cyclohexylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 27 (l-(3-[(2-Cvclohexvl-l-hvdroxycarbamoylethyl)-(4-methoxv-benzene-sulfonvI)20 aminolpropionvl)piperidin-4-vl)methvlcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 625 (M+l).
EXAMPLE 28 l-(3-[(2-Cyclohexvl-l-hvdroxycarbamovlethvl)(4-methoxv-benzenesulfonvBaminolnropionvllpiperidine-4-carboxylic acid ethyl ester 25 Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 568 (M+l).
The title compounds of Examples 29-30 were prepared analogously to that described in Example 1 using D-l-naphthylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
AP/P/ 97 / 0 1 0 78
AP.00733
-30EXAMPLE 29 (l-f3-[(l-Hvdroxvcarbamoyl-2-naphthalen-l-vlethvD-(4-methoxv-benzenesulfonvl)aminolpropionvllniperidin-4-yr)methvlcarbamic acid tert-butyl ester
Coupled with methyIpiperidin-4-yIcarbamic acid tert-butyl ester.
EXAMPLE 30
1- (3-f(l-Hvdroxvcarbamoyl-2-naphthalen-l-ylethyl)(4-methoxvbenzene-sulfonvD aminolpropionvnpiperidine-4-carboxvlic acidethyl ester Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 611 (M+l).
EXAMPLE 31
2-Cvclohexyl-N-hvdroxv-2-{(4-methoxvbenzenesulfonyl)-f3-(4-methyI-aminopiperidin-l-vl)-3-oxopropyl]-amino)acetamide
A solution of l-{3-[(cyclohexylhydroxycarbamoylmethyl)(4-methoxybenzenesulfonyl)-amino]-propionyl }piperidin-4-yl)methylcarbamic acid tert-butyl ester (1.53 grams, 2.50 mmol) in methylene chloride (70 mL) was bubbled with hydrochloric acid gas for 2 minutes. The ice bath was removed and the reaction mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated and twice methanol was added to the residue and evaporated leaving
2- cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidinl-yl)-3-oxopropyl]-amino}acetamide hydrochloride dihydrate as a white solid (1.22 grams, 90%). MS: 511 (M+l). Analysis calculated for C24H39C1N4O6S*2H2O: C, 49.43; H, 7.43; N, 9.61. Found: C, 49.86; H, 7.23; N, 9.69.
The title compounds of Examples 32-41 were prepared analogously to that described in Example 33 using the starting material indicated.
EXAMPLE 32
N-Hvdroxv-2-((4-methoxvbenzenesulfonvDf3-(4-methvIaminopiperidin-l-vr)-3oxopropvllamino)-3-methvlbutvramide hydrochloride
Starting material: (1 - {3 - [(1 -hydroxycarbamoyl-2-methylpropyl)(4-methoxybenzene30 sulfonyl)-amino]propionyl}piperidin-4-yl)-methylcarbamic acid tert-butyl ester using methyl-piperidin-4-ylcarbamic acid tert-butyl. MS: 471 (M+l).
AP/P/ 9 7 / 0 1 0 78
AP.0 073 J
-31EXAMPLE 33
2-{(4-MethoxvbenzenesuIfonvl)-f3-(4-methylaminopiperidin-l-vl)-3-oxo-propyUamino)4-methylpentanoic acid hvdroxyamide hydrochloride
Starting material: (1 - {3- [(1 -hydroxycarbamoy l-3-methylbutyl)(4-methoxybenzene5 sulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester.
Melting Point 170-173°C. MS: 485 (M+l).
EXAMPLE 34
2- ((4-Methoxvbenzenesulfonvl)-f3-(4-methvlaminopiperidin-l-vl)-3-oxo-propyll aminolhexanoic acid hvdroxyamide hydrochloride 10 Starting material: (l-{3-[(l-hydroxycarbamoylpentyl)-(4-methoxybenzenesulfonyl)amino]-propionyl}piperidin-4-yl)methyl-carbamic acid tert-butyl ester. MS: 485 (M+l). Analysis calculated for C2,H34N4O6S*HC1*4H2O: C, 43.5; H, 7.48; N, 9.67. Found: C, 43.65; H, 7.03; N, 9.79.
EXAMPLE 35
2-((4-Methoxvbenzenesulfonvl)-f3-(4-methvlaminopiperidin-l-vI)-3-oxo-propyll aminol-4,4-dimethyInentanoic acid hvdroxyamide hydrochloride Starting material: (1 -{3-[( 1 -hydroxy-carbamoyl-3,3-dimethylbutyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 499 (M+l).
EXAMPLE 36
N-Hvdroxv-2-f(4-methoxybenzenesulfonvl)-i3-f4-methylaminopiperidin-l-yl)-3oxopropyllamino)-3-phenvlpropionamide hydrochloride
Starting material: (1 - {3 - [(1 -hydroxycarbamoy l-2-phenylethyl)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidin-4-yI)methylcarbamic acid tert-butyl ester.
MS: 519 (M+l).
EXAMPLE 37
3- (4.Fluorophenvl)-N-hvdroxy-2-((4-methoxvbenzenesulfonvl)-f3-(4-methylamino piperidin-l-vl)-3-oxo-nropyIlamino)propionamide hydrochloride
Starting material: (1 -{3-[[2-(4-fluorophenyl)-l-hydroxycarbamoylethyl]-(4-methoxy30 benzenesulfonyl)amino]propionyl}-piperidin-4-yl)methylcarbamic acid tert-butyl ester
AP/P/ 9 7 / 0 1 0 78
AP.0073J
-32(Example 21). MS: 537 (M+l). Analysis calculated for C25H33FN4O6S»HC1»2H2O: C, 49.30; H, 6.29; N, 9.20. Found: C, 49.14; H, 5.82; N, 9.24.
EXAMPLE 38
N-Hvdroxv-2-f(4-methoxvbenzenesulfonvi)-f3-(4-methylaminopiperidin-l-yl)-35 oxopropvllaminol-4-phenvlbutyramide hydrochloride
Starting material: (1 - {3 - [(1 -hydroxycarbamoyl-3 -phenylpropyl)(4-methoxybenzenesulfonyl)amino] propionyl }piperidin-4-yl)methylcarbamic acid tert-butyl ester. Melting Point 160-170°C. MS: 533 (M+l). Analysis calculated for C26H36N4O6S*HC1*1.5H2O: C, 52.38; H, 6.76; N, 9.40. Found: C, 52.25; H, 6.40;
N, 9.00.
EXAMPLE 39
3-tert-Butoxv-N-hvdroxv-2-f(4-methoxvbenzenesulfonvl)-i3-(4-methyl-aminopiperidin-l-vl)-3-oxopropvIl-amino)propionamide hydrochloride Starting material: (1 -{3-[(2-tert-butoxy-l-hydroxycarbamoylethyl)(4-methoxy15 benzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 515 (M+l).
EXAMPLE 40
3-Cvclohexyl-N-hvdroxy-2-{(4-methoxvbenzenesuIfonvl)-f3-(4-methyl-aminopiperidin-l-vD-3-oxopropyllamino)propionamide hydrochloride
Starting material: (l-{3-[(2-cyclohexyl-l-hydroxycarbamoylethyl)-(4-methoxybenzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 525 (M+l).
EXAMPLE 41
N-Hvdroxy-2-((4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-l-vl)-325 oxopropyllaminol-3-naphthalen-l-ylpropionamide hydrochloride
Starting material: (1 -{3-[( 1 -hydroxy-carbamoyl-2-naphthalen-1 -ylethyl)-(4-methoxybenzenesulfonyl)amino]propionyl} -piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 569 (M+l).
AP/P/ 9 7 / 0 1 0 78
AP. (ΤΟ 7 3 3
-33EXAMPLE 42 l-(3-K'Cvclohexvlhvdroxvcarbamovlmethyl)-(4-methoxvbenzenesulfonyI)-aminolpropionvl)piperidine-4-carboxylic acid
To a solution of l-{3-[(cyclohexylhydroxycarbamoylmethyl)(4-methoxy- .
benzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester (0.62 grams, 1.16 mmol) (Example 17) in ethanol (45 mL) and water (5 mL) was added lithium hydroxide monohydrate (0.24 grams, 5.72 mmol). After stirring for 3 hours at room temperature ethanol-washed Amberlite IR-120 plus ion exchange resin (6 grams) was added. Stirring was continued for 15 minutes and then the mixture was filtered. The filtrate was concentrated in vacuo to give l-{3-[(cyclohexylhydroxycarbamoylmethyl)-(4-methoxy-benzenesulfonyl)amino]propi onyl}-piperidine-4-carboxylic acid monohydrate as a white solid (0.52 grams, 88%). MS: 526 (M+l). Analysis calculated for CMH35N3O,S*H2O: C, 53.03; H, 6.86; N, 7.73. Found: C, 53.53; H, 7.15; N, 7.70.
The title compounds of Examples 43-53 were prepared analogously to that described in Example 45 using the starting material indicated.
EXAMPLE 43 l-{3-ftl-Hvdroxvcarbamovl-2-methvlpropyl)(4-methoxvbenzene-sulfonyl)aminol propionyl)piperidine-4-carboxvlic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-2-methylpropyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 486 (M+l).
EXAMPLE 44 (4-f3-ftl-HvdroxvcarbamovI-2-methvlpropvl)(4-methoxvbenzene-sulfonvl)amino1 propionyl) niperazin-l-vl)acetic acid
Starting material: (4-{3-[(1 -hydroxycarbamoyl-2-methylpropyl)(4-methoxybenzenesulfonyl)amino]-propionyl}piperazin-l-yl)acetic acid ethyl ester (Example 8). MS: 500 (M+l).
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-34EXAMPLE 45 l-{3-f(l-Hvdroxvcarbamovl-3-methvlbutvl)-(4-methoxvbenzenesulfonyl)-aminolpropionvnpiperidine-4-carboxvlic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-3-methylbutyl)(4-methoxybenzene5 sulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. Melting Point 118120°C. MS: 500 (M+l).
EXAMPLE 46 l-i3-i(l-Hvdroxvcarbamovlpentvl)(4-methoxvbenzenesulfonvl)aminol-propionvn piperidine-4-carboxvlic acid
Starting material: 1-{3-((1-hydroxycarbamoylpentyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 500 (M+l).
EXAMPLE 47 l-f3-f(l-Hvdroxvcarbamoyl-3,3-dimethvlbutvl)(4-methoxv-benzene-suIfonvl)aminolpropionvHniperidine-4-carboxvlic acid 15 Starting material: I-{3-((1 -hydroxycarbamoyl-3,3-dimethylbutyl)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 514 (M+l). EXAMPLE 48 l-{3-f(l-Hvdroxvcarbamovl-2-phenvlethvI)-(4-methoxybenzenesulfonyl)-aminolpropionvnpiperidine-4-carboxvlic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-2-phenyl-ethy l)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 534 (M+l).
EXAMPLE 49 l-(3-H2-(4-Fluorophenvl)-l-hvdroxvcarbamovlethvll(4-methoxvbenzene-sulfonvl) aminolpropionyI|piperidine-4-carboxvlic acid 25 Starting material: l-{3-([2-(4-fluorophenyl)-l-hydroxycarbamoylethyl](4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester.
MS: 552 (M+l). Analysis calculated form C25H3oFN3O8S*0.5H2O: C, 53.56; H, 5.57; N, 7.50. Found: C, 53.53; H, 5.39; N, 7.28.
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-35EXAMPLE 50
- (3- f(l-Hvdroxyearbamovl-3-phenvlpropyI)(4-methoxybenzenesuIfonvI)-aminolpropionyl)piperidine-4-carboxylic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-3 -phenyl-propyl)-(4-methoxybenzene5 sulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. Melting Point 8592°C. MS: 598 (M+l).
EXAMPLE 51 l-(3-f(2-tert-Butoxv-l-hvdroxvcarbamoylethvI)f4-methoxvbenzene-sulfonvl)amino1nropionvl)pineridine-4-carboxvIic acid
Starting material: l-{3-[(2-tert-butoxy-l-hydroxycarbamoylethyl)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester.
MS: 529 (M+l).
EXAMPLE 52 l-{3-l(2-CvcIohexvl-l-hvdroxycarbamovIethvl)(4-methoxvbenzene-sulfonvl)15 aminol propionyl) piperidine-4-carboxyIic acid
Starting material: 1 - {3 - [(2-cyclohexy 1-1 -hydroxycarbamoy lethy l)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester.
MS: 540 (M+l).
EXAMPLE 53 l-i3-f(l-Hvdroxvcarbamovl-2-naphthalen-l-ylethvI)(4-methoxvbenzene-sulfonyl) aminolpropionyl)piperidine-4-carboxylic acid
Starting material: 1 - {3-[( 1 -hydroxycarbamoyl-2-naphthalen-1 -ylethyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acidethyl ester.
MS: 584 (M+l).
EXAMPLE 54
N-Hvdroxv-2-H3-14-(2-hvdroxvethvDpiperazin-l-yll-3-oxopropyl)-(4-methoxvben zenesulfonvDaminol-3-methylbutvramide (A) To a solution of 2-[(2-carboxyethyl)-(4-methoxybenzenesulfonyl)amino]-3methylbutyric acid benzyl ester(prepared staring from D-valine benzyl ester according to the procedure of Example 1, steps A to D) (1.35 grams, 3.0 mmol) in methylene chloride (45 mL) were added sequentially triethylamine (0.92 mL, 6.9 mmol),
AP/P/ 97/01078
AP .0-0 7 3 3
-362-piperazin-l-ylethanol (0.43 grams, 3.3 mmol) and (benzotriazol-l-yloxy)tris(dimethylamino)-phosphonium hexafluoroborate (1.53 grams, 3.45 mmol). The resulting mixture was stirred for 16 hours at room temperature and then concentrated in vacuo. The residue was taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 5% methanol in chloroform to afford 2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]-3-oxopropyl}(4-methoxybenzenesulfonyl)amino]-3-methy lbutyric acid benzyl esteras an oil (1.40 grams, 83%). Conversion to the hydrochloride salt was subsequently carried out using anhydrous hydrochloric acid in cold (O’C) methylene chloride.
(B) To a solution of 2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]-3-oxopropyl}(4-methoxy-benzenesulfonyl)amino]-3-methylbutyric acid benzyl ester hydrochloride (1.49 grams, 2.49 mmol) in ethanol (80 mL) was added 10% palladium on activated carbon (0.11 grams). The mixture was agitated under 3 atmospheres hydrogen in a Parr shaker for 16 hours. The catalyst was removed by filtration through nylon (pore size 0.45 μια) and the solvent was evaporated leaving 2-[{3-[4-(2-hydroxyethyl)piperazinl-yl]-3-oxo-propyl}(4-methoxybenzenesulfonyl)amino]-3-methylbutyric acid hydrochloride as a white solid (1.16 grams, 92%).
(C) To a solution of 2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]-3-oxo20 propyl}(4-methoxy-benzenesuifonyl)amino]-3-methylbutyric acid hydrochloride (1.10 grams, 2.17 mmol) in methylene chloride (50 mL) and Ν,Ν-dimethylformamide (0.5 mL) were added sequentially O-benzylhydroxylamine hydrochloride (0.41 grams, 2.60 mmol), triethylamine (0.91 mL, 6.5 mmol) and (benzotriazol-l-yloxy)tris(dimethylamino)-phosphonium hexafluoroborate (1.20 grams, 2.71 mmol). The resulting mixture was stirred for 16 hours at room temperature and then concentrated in vacuo. The residue was taken up in ethyl acetate and washed successively with saturated sodium bicarbonate solution, water and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 3% methanol in chloroform to afford N-benzyloxy30 2-[{3 - [4-(2-hy droxy ethy l)piperazin-1 -y 1] -3 -oxopropyl} (4-methoxybenzenesulfony l)am ino]-3-methylbutyramide as a clear oil (0.85 grams, 68%). Conversion to the
AP/P/ 9 7 0 1 0 7 8
AP . Ο Ο 7 3 3
-37hydrochloride salt was subsequently carried out using anhydrous hydrochloric acid in cold (0*C) methylene chloride.
(D) To a solution of N-benzyloxy-2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide hydrochloride (0.39 grams, 0.63 mmol) in methanol (30 mL) was added 5% palladium on barium sulfate (0.19 grams). The mixture was agitated under 3 atmospheres hydrogen in a Parr shaker for 2.25 hours. The catalyst was removed by filtration through nylon (pore size 0.45 μτη) and the solvent was evaporated to a tan foam which was chromatographed on silica gel eluting with 15% methanol in chloroform containing 0.5% ammonium hydroxide. Clean fractions containing the desired product were taken up in saturated sodium bicarbonate solution. The resulting mixture was extracted several times with ethyl acetate and the combined extracts were concentrated to afford N-hy droxy-2-[ {3 - [4-(2-hydroxyethyl)piperazin-1 -yl]-3-oxopropyl} -(4-methoxybenzen esulfonyl)amino]-3-methyl-butyramide as an oil. The hydrochloride salt (0.20 grams,
61%) was formed using anhydrous hydrochloric acid in cold (0°C) methanol. MS: 487 (M+l). Analysis calculated for C2,H34N4O7S*HCl*0.5H2O: C, 47.41; H, 6.82; N, 10.53. Found: C, 47.41; H, 7.11; N, 9.91.
The title compounds of Examples 55-57 were prepared analogously to that described in Example 58 using the indicated amine in step A.
EXAMPLE 55
2-H3-(4-Dimethvlaminopiperidin-l-vD-3-oxopropvlI(4-methoxvbenzene-sulfonvD aminol-N-hydroxy-3-methvlbutvramide
Coupled with dimethylpiperidin-4-ylamine. MS: 485 (M+l).
EXAMPLE 56
N-Hvdroxv-2-[{3-f4-(3-hvdroxvpropvDpiperazin-l-vn-3-oxopropvn-(4-methoxvbenzenesuIfonvl)amino]-3-methvlbutyramide
AP/P/ 9 7.0 1 0 78
Coupled with 3-piperazin-l-ylpropan-l-ol. MS: 500 (M+l).
AP . Ο Ο 7 3 3
-38EXAMPLE 57
2-K3-ri.4’lBipiperidmvl-r-yl-3-oxopropyl)-(4-inethoxvbenzenesulfonyI)-aniinol-Nhydroxy-3-methvIbutyraTnide
Coupled with using [l,4’]bipiperidinyl. MS: 525 (M+l). Analysis calculated for 5 C25H40N4O6S*HCl»1.5H2O: C, 51.05; H, 7.54; N, 9.52. Found: C, 50.80; H, 7.45;
N, 9.36.
EXAMPLE 58 l-{3-r(l-Hydroxycarbamoyl-2-methvlpropyl)-(4-phenoxybenzenesulfonvl) aminol propionyl! piperidine-4-carboxylic acid ethyl ester 10 The title compound was prepared analogously to that described in Example 1 using D-valine benzyl ester and 4-phenoxybenzenesulfonyl chloride as the starting materials in step A and piperidine-4-carboxylic acid ethyl ester in step E. Analysis calculated for C28H37N3O8S. O.1CH2C12: C, 57.78; H, 6.42; N, 7.19. Found: C, 57.46; H, 6.41; N, 7.11.
EXAMPLE 59 l-f3-i(l-HvdroxvcarbamovI-2-methvIpropvl)-(4-phenoxvbenzenesulfonvl) aminol propionyl! piperidine-4-carboxvlic acid
The title compound was prepared analogously to that described in Example 42 using l-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4-phenoxybenzenesulfonyl)amino] 20 propionyl]piperidine-4-carboxylic acid ethyl ester (Example 58) as the starting material.
MS: 548 (M+l). Analysis calculated for C26H33N3O8S. 0.5H2O: C, 56.10; H, 6.16; N, 7.75. Found: C, 55.99; H, 6.06; N, 7.43.

Claims (11)

  1. A compound of the formula
    Having now particularly described and ascertained my/our said invention and <n v, ha: manner the same is to be performed I/we declare that what I/we claim is —
    H0-NI
    H
    II
    -C, <CH2)n
    R3 |
    C-N
    R4 \ o \// s\ o a or the pharmaceutically acceptable salts thereof, wherein n is 1 to 6;
    X is OR1 wherein R1 is as defined below; azetidinyl, pyrrolidinyl, piperidinyl, morpholinyi, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl,
    15 tetrahydroisoquinolinyl, piperazinyl or a bridged diazabicycloalkyl ring selected from the group consisting of
    AP/P/ 9 7 0 1 0 7 8 a
    AiP . 0 0 7 3 3
    N :n (CH2)r wherein r is 1, 2 or 3; m is 1 or 2; and p is 0 or 1;
    wherein each heterocyclic group may optionally be substituted by one or two groups selected from hydroxy, (Ci-C6)alkyl, (Ci-C6)alkoxy, (Cj-Cjojacyl, (C1-C10)acyloxy, (C6C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl(Cj-C6)alkyl, (C5-C9)heteroaryl (CrC^alkyl, hydroxy (C,-C6)alkyl, (CrC6)alkoxy (C,-C6)alkyl, (C.-QacyloxyiCj-CJalkyl, (Cr C6)alkylthio, (Cj-C6)alkylthio (Cj-Cejalkyl, (C6-Ci0)arylthio, (C6-C10) arylthioCCjC6)alkyl, R9RI0N, R9R10NSO2, R9R10NCO, R9R10NCO(C,-C6)alkyl wherein R9 and R10 are each independently hydrogen, (Cj-C^alkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6Cio)aryl (Cj-CJalkyl or (C5-C9)heteroaryl (CrCJalkyl or R9 and R10 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpolinyl ring; R12SO2, R12SO2NH wherein R12 is trifluoromethyl, (Q-CJalkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6C10)aryl(C,-C6)alkyl or (C5-C9)heteroaryl (Cj-C6)alkyl; R13CONR9 wherein R9 is as defined above and R13 is hydrogen, (Cj-C6)alkyl, (C2-C6)alkoxy, (C0-C10)aryl, (C5C9)heteroaryl, (C1-C6)aryl(C1-C6)alkyl(C6-C10)aryl(Ci-C6)alkoxy or (Cs-C^heteroaryXCjC6)alkyl; R14OOC, R14OOC(C1-C6)alkyl wherein R14 is (Cj-C6)alkyl, (C6-C10)aryl, (C5C9)heteroaryl, (C6-C10)aryl (Cj-C6)alkyl, 5-indanyl, CHR5OCOR6 wherein R5 is hydrogen or (Cj-CJalkyl and R6 is (Cj-C6)alkyl, (C2-C6)alkoxy or (C6-C10)aryl; CH2CONR7R8 wherein R7 and R8 are each independently hydrogen or (Ci-C6)alkyl or may be taken together with the nitrogen to which they are attached to form an
    AP/P/9 7. ύ 1 0 78
    AP.ύ Ο 7 3 3
    -41azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring; or R15O (CjC^alkyl wherein R15 is H2N(CHR16)CO wherein R16 is the side chain of a natural D- or L-amino acid;
    R1 is (C6-C10)aryl, (C5-C9)heteroaryl, (C^CjojaryKCj-CeJalkyl, 5-indariyl,
    5 CHR5OCOR6 or CH2CONR7R8 wherein R5, R6, R7 and R8 are as defined above;
    R3 and R4 are each independently selected from the group consisting of hydrogen, (Ci-C6)alkyl, trifluoromethyi, trifluoromethyl(Ci-C6)alkyl, (C,-C6)alkyl (difluoromethylene), (C1-C3)alkyl(difluoromethylene)(C1-C3)alkyl, (C6-CJ0)aryl, (C5C9)heteroaryl, (Cg-C^jaryhCj-C^alkyi, (Cj-CcOheteroaryliCj-Cgjalkyl, (C6-C10)aryl(C610 CI0)aryl, (C6-C10)aryl(C6-C10)aryl(C1-C6)alkyl, (C3-C6)cycloalkyl, (Cj-CgjcycloalkyKCr C6)alkvl,hydroxy(C1-C6)alkyl,(C1-C10)acyloxy(C1-C6)alkyl,(C1-C6)alkoxy(C1-C6)alkyl, (C,-Ci0)acylamino(C,-C6)alkyl, piperidyl, (C,-C6)alkylpiperidyl, (C0- C10)aryl(Cr C6)alkoxy(C1-C6)alkyl, (Q-C^heteroaryhCj-CJalkoxytCj-C^alkyl, (Cj-C^alkylthioiCjC6)alkyl, (C6-C10)arylthio(CrC6)alkyl, (C,-C6)alkylsulfinyl(C1-C6)alkyl, (C615 CjojarylsulfinyfrCj-CJalkyl, (Q-C^alkylsulfonyKCpCejalkyl, (C6-C10)arylsulfonyl(CIC6)alkyl, aminoCCpC^alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((Ci-C6)alkylamino)2(C1C6)alkyl, R17CO(C,-C6)alkyl wherein R17 is R14O or R7R8N wherein R7, R8 and R14 are as defined above; or R18(C,-C6)alkyl wherein R18 is piperazinyl, (C,C10)acylpiperazinyl, (C6-Ci0)arylpiperazinyl, (C5-C9)heteroarylpiperazinyl, (Cr
    20 C6)alkylpiperazinyl, (Ce-C^ary^Cj-CUalkylpiperazinyl, (Cs-CojheteroaryltCjC6)alkylpiperazinyl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperidyl, (C]-C6)alkylpiperidyl, (C6-C10)arylpiperidyl, (C5-C9)heteroarylpiperidyl, (C6-C10)aryl(CiC6)alkylpiperidyl, (C5-C9)heteroaryl(Ci-C6)alkylpiperidyl or (Ci-C10)acylpiperidyl;
    or R3 and R4 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl,
    25 thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula
    AP/P/ 9 7.01078
    N
    I
    R
    AP. ΰ Ο 7 3 3
    -42wherein R21 is hydrogen, (Cj-Cjojacyl, (CpC^alkyl, (C6-C10)aryl(C1-C6)alkyl, (C5CgjheteroaryfrCj-C^alkyl or (Ci-C6)alkylsulfonyl; and
    Q is (C,-C6)alkyl, (C6-C10)aryl, (C6-C10)aryloxy(C6-Ci0)aryl, (C6-C10)aryl(C6C10)aryl, (C6-C10)aryl(C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryloxy(C5-C9)heteroaryl, (C5C9)heteroaryl, (C,-C6)alkyl(C6-C10)aryl, (Ci-C6)alkoxy(C6-C10)aryl, (C6-C10)aryl(Cr C6)alkoxy(C6-CI0)aryl,(C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl,(C5-C9)heteroaryloxy(C6C10)aryl, (Cj-C^alkyKCj-Csjheteroaryl, (Ci-C6)alkoxy(C5-C9)heteroaryl, (C6C10)aryl(CrCJalkoxy(C5-C9)heteroaryl, (C5-C9)heteroaryloxy(C5-C9)heteroaryl, (C6CmjaryloxyCCj-CsJalkyl, (C5-C9)heteroaryloxy(CrC6)alkyl, (Cj-C^alky^CeCiojaryloxyiCs-C^iaryl/Cj-CejalkyKCs-C^heteroaryloxyiCe-Ciojaryl/Ci-CeialkylCCeC10)aryloxy(C5-C9)heteroaryl, (Cj-CJalkoxyiCe-C^aryloxyCCg-C^aryl, (Cr C6)alkoxy(C5-C9)heteroaryloxy(C6-C10)aryl or (C1-C6)alkoxy(C6-Ci0)aryloxy(C5C9)heteroaryl wherein each aryl group is optionally substituted by fluoro, chloro, bromo, (Ci-C6)alkyl, (Cj-C^alkoxy or perfluoro(Ci-C3)alkyl;
    with the proviso that X must be substituted when defined as azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl, (C1-C10)acylpiperazinyl, (CxC6)alkylpiperazinyl, (C6-C10)arylpiperazinyl, (C5-C9)heteroarylpiperazinyl or abridged diazabicycloalkyl ring.
  2. 2. A compound according to claim 1, wherein n is 2.
  3. 3. A compound according to claim 1, wherein either R3 or R4 is not hydrogen.
  4. 4. A compound according to claim 1, wherein Q is (C]-C6)alkoxy(C6C10)aryl, (Ce-C^jaryKCrCJalkoxyiCe-Cjoiaryl, phenoxy(C6-C10)aryl, 4fluorophenoxy(C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryl or (C!-C6)alkyl(C6C10)aryloxy(C6-C10)aryl.
  5. 5. A compound according to claim 1, wherein X is indolinyl or piperidinyl.
  6. 6. A compound according to claim 1, wherein n is 2; either R3 or R4 is not hydrogen; Q is (C1-C6)alkoxy(C6-C10)aryl, (C6-C10)aryl(C1-C6)aIkoxy(C6-C10)aryl, 4fluorophenoxy(C6-Cio)aryl, phenoxy (C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryl or (Cr C6)alkyl(C6-C10)aryloxy(C6-C10)aryl; and X is indolinyl or piperidinyl.
    AP/P/ 9
  7. 7 / 0 1 0 78
    AP . 0 Ο 7 3 3
    -437. A compound according to claim 1, wherein said compound is selected from the group consisting of:
    3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionic acid indan-5-yl ester;
    5 Acetic acid l-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzenesulfonyl)-amino]propionyl}piperidin-4-yl ester;
    2-Cyclohexyl-N-hydroxy-2-[[3-(4-hydroxypiperidin-l-yl)-3-oxopropyl]-(4-methoxy-benzenesulfonyl)amino]acetamide;
    Benzoicacidl-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzene10 sulfonyl)amino]propionyl}piperidin-4-yl ester;
    N-Hydroxy-2-[[3-(4-hydroxypiperidin-l-yl)-3-oxopropyl]-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
    1- {3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid;
    15 1 -{3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester;
    2- Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}acetamide;
    3- (4-Chlorophenyl)-N-hydroxy-2-{(4-methoxybenzenesulfonyl)20 [3-(4-methylaminopiperidin-l-yl)-3-oxopropyl]amino}propionamide;
    3-Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}propionamide;
    N-Hydroxy-2-[{3-[4-(2-hydroxy-2-methylpropyl)piperazin-l-yl]3-oxopropyl}-(4-methoxy-benzenesulfonyl)amino]-3-methylbutyramide;
    25 2,2-Dimethylpropionicacid2-(4-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4methoxy-benzenesulfonyl)amino]propionyl}piperazin-l-yl)ethyl ester;
    Benzoic acid 2-(4-{3-(( l-hydroxycarbamoyl-2-methylpropyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperazin-l-yl)-ethyl ester;
    2-Cyclohexyl-N-hydroxy-2-[{3-[4-(2-hydroxyethyl)piperazin30 1 -yl]-3-oxopropyl} -(4-methoxybenzenesulfonyl)amino]acetamide;
    AP/P/ 97 , u 10 78
    AP . Ο Ο 7 3 3
    -442-Hydroxy-2-[{3-[5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
    2-{(4-Benzyloxybenzenesulfonyl)-[3-(4-hydroxypiperidin-l-yl)3-oxopropyl]amino}-N-hydroxy-3-methylbutyramide;
    5 2-Cyclohexyl-2-([4-(4-fluorophenoxy)benzenesulfonyl]-(3-(4-hydroxypiperidin-1 -yl)-3-oxopropyl]-amino}-N-hydroxyacetamide;
    2- {[4-(4-Butylphenoxy)benzenesulfonyl]-[3-(4-hydroxypiperidinl-yl)-3-oxopropyl]-amino}-N-hydroxy-3-methylbutyramide;
    l-{(4-Methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-l-yl)-3-oxo10 propyl]amino}-cyclopentanecarboxylic acid hydroxyamide;
    4-(3-((1 -Hydroxy carbamoyl-2-methylpropyl)-(4-methoxybenzenesulfonyl)amino]-propionyl}piperazine-2-carboxylic acid ethyl ester;
    3- [(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
    15 3-((1 -Hydroxycarbamoylpentyl)-(4-methoxybenzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
    1-(3-((1 -Hydroxycarbamoyl-2-methylpropyl)-(4-phenoxybenzenesulfonyl)amino] propionyl] piperidine-4-carboxylic acid.
    3-[[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-(l-hydroxy20 carbamoyl-2-methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester; and 3-[[4-(4-Fluorophenoxy)-benzenesulfonyl]-(l-hydroxycarbamoyl-2methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester.
  8. 8. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, mucular
    25 degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NS AID’S and analgesics and in combination with cytotoxic anti cancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the
    30 production of tumor necrosis factor (TNF) in a mammal, including a human,
    AP . Ο Ο 7 3 3
    -45comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.
  9. 9. A method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human,
    5 comprising administering to said mammal an effective amount of a compound of claim 1.
  10. 10. A method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, compounds of formula I may be used in
    10 combination with standard NS AID’S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (INF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of claim 1, effective in treating such a
  11. 15 condition.
APAP/P/1997/001078A 1996-08-23 1997-08-21 Arylsulfonylamino hydroxamic acid derivatives. AP733A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2467596P 1996-08-23 1996-08-23

Publications (2)

Publication Number Publication Date
AP9701078A0 AP9701078A0 (en) 1997-10-31
AP733A true AP733A (en) 1999-02-12

Family

ID=21821806

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001078A AP733A (en) 1996-08-23 1997-08-21 Arylsulfonylamino hydroxamic acid derivatives.

Country Status (31)

Country Link
US (1) US6153609A (en)
EP (1) EP0922030A1 (en)
JP (1) JP2000501423A (en)
KR (1) KR20000068248A (en)
CN (1) CN1228083A (en)
AP (1) AP733A (en)
AR (1) AR009292A1 (en)
AU (1) AU711585B2 (en)
BG (1) BG103191A (en)
BR (1) BR9711223A (en)
CA (1) CA2264284A1 (en)
CO (1) CO4600003A1 (en)
EA (1) EA199900139A1 (en)
GT (1) GT199700094A (en)
HN (1) HN1997000110A (en)
HR (1) HRP970453A2 (en)
ID (1) ID18063A (en)
IL (1) IL128189A0 (en)
IS (1) IS4958A (en)
MA (1) MA24307A1 (en)
NO (1) NO990821L (en)
OA (1) OA10978A (en)
PA (1) PA8435301A1 (en)
PE (1) PE99698A1 (en)
PL (1) PL331895A1 (en)
SK (1) SK21499A3 (en)
TN (1) TNSN97139A1 (en)
TR (1) TR199900387T2 (en)
TW (1) TW397823B (en)
WO (1) WO1998007697A1 (en)
ZA (1) ZA977561B (en)

Families Citing this family (320)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
EA003294B1 (en) * 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Metalloproteinase inhibitors, pharmaceutical compositions, their constituents, and their pharmaceutical use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
DE69805473T2 (en) * 1997-08-08 2003-01-16 Pfizer Products Inc., Groton Arylsulfonylaminohydroxamsäurederivate
PA8469601A1 (en) * 1998-04-10 2000-09-29 Pfizer Prod Inc PROCEDURE FOR RENTING STERICALLY IMPAIRED SULFONAMIDES
PA8469301A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc PROCEDURES FOR THE PREPARATION OF HYDROXAMIC ACIDS.
GT199900044A (en) * 1998-04-10 2000-09-14 PROCEDURES FOR PREPARING PHENOXYPHENYL SULFONYL HALIDES.
DK0952148T3 (en) * 1998-04-10 2004-09-20 Pfizer Prod Inc Cyclobutylaryloxyarylsulfonylaminohydroxamic acid derivatives
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
DE60003863T2 (en) * 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
DE19920907A1 (en) * 1999-05-06 2000-11-09 Basf Ag Preparation of cyclohexylglycine ester derivatives comprises reacting cyclohexylglycine derivatives with methanesulfonic acid and benzyl alcohol derivative in organic solvent
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
SE0000382D0 (en) 2000-02-07 2000-02-07 Astrazeneca Ab New process
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
EP1440057A1 (en) 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
AU2002361096A1 (en) * 2001-12-27 2003-07-15 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
CA2478050A1 (en) 2002-03-01 2003-09-12 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
US20050232915A1 (en) * 2002-03-08 2005-10-20 Motowo Nakajima Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
DK3000810T3 (en) 2002-03-13 2017-10-16 Array Biopharma Inc N3-ALKYLED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CA2510850A1 (en) 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
WO2004056353A2 (en) * 2002-12-20 2004-07-08 Novartis Ag Device and method for delivering mmp inhibitors
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
AP2114A (en) 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
US7538111B2 (en) * 2003-03-25 2009-05-26 Laboratoires Fournier S.A. Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
ES2351395T3 (en) 2003-08-13 2011-02-04 Pfizer Products Inc. ANTI-IGF-1R MODIFIED HUMAN ANTIBODIES.
ATE412655T1 (en) 2003-08-29 2008-11-15 Pfizer THIENOPYRIDINPHENYLACETAMIDE AND DERIVATIVES THEREOF SUITABLE AS NEW ANTIANGIOGENIC AGENTS
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
JP4768628B2 (en) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド MEK bicyclic inhibitors and methods of use thereof
NZ552091A (en) 2004-07-16 2009-09-25 Pfizer Prod Inc Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
EP1967516B1 (en) 2005-05-18 2009-11-04 Array Biopharma, Inc. 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulphate
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
ATE483463T1 (en) 2006-04-18 2010-10-15 Ardea Biosciences Inc PYRIDONE SULFONAMIDE AND PYRIDONE SULFONAMIDE AS MEK INHIBITORS
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
CN101663279A (en) 2007-01-19 2010-03-03 阿迪生物科学公司 inhibitors of mek
AU2008240359B2 (en) 2007-04-18 2014-06-26 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
BRPI0819529A2 (en) 2007-12-19 2015-05-26 Genentech Inc "compound of formula I, pharmaceutical composition, method for inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal and method for treating an inflammatory disease in a mammal"
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (en) 2008-01-04 2010-11-12 Intellikine Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS.
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP3009436B1 (en) 2008-07-08 2019-06-05 Intellikine, LLC Kinase inhibitors and methods of use
JP5836125B2 (en) 2008-10-16 2015-12-24 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Fully human antibodies against high molecular weight melanoma-related antigens and uses thereof
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
BRPI1008749B8 (en) 2009-02-05 2021-05-25 Immunogen Inc benzodiazepine derivative compounds, their conjugates, pharmaceutical composition, their use and their preparation processes
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
ES2543608T3 (en) 2009-03-27 2015-08-20 Ardea Biosciences, Inc. Dihydropyridine sulfonamides and dihydropyridine sulfonamides as MEK inhibitors
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
US20120128670A1 (en) 2009-07-31 2012-05-24 OSI Pharmaceuticals, LLC mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
ES2534358T3 (en) 2009-10-13 2015-04-21 Allomek Therapeutics, Llc Innovative MEK inhibitors useful in the treatment of diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PH12012500901A1 (en) 2009-11-05 2016-08-05 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
JP5841072B2 (en) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド CD20 antibody and use thereof
SI2534153T2 (en) 2010-02-12 2024-07-31 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino (5,4,3-cd)indol-6-one
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA3084173A1 (en) 2010-05-17 2011-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued_-3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2582727B8 (en) 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
ES2543151T3 (en) 2010-10-20 2015-08-17 Pfizer Inc 2-Pyridine derivatives as Smoothened receptor modulators
JP2013545749A (en) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
UA120696C2 (en) 2011-02-15 2020-01-27 Імуноген, Інк. METHOD OF OBTAINING CONJUGATES
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
TR201905909T4 (en) 2011-04-19 2019-05-21 Pfizer Combinations of anti-4-1bb antibodies and adcc inducing antibodies for cancer therapy.
JP2014519813A (en) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
MX365160B (en) 2011-05-04 2019-05-24 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases.
EP4085899A1 (en) 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2671748T3 (en) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
JP6029668B2 (en) 2011-08-29 2016-11-24 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
CN102408411B (en) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 Hydroximic acid compound containing quinolyl and preparation method thereof, and drug composition containing the compound and use thereof
PE20141228A1 (en) 2011-09-22 2014-10-01 Pfizer DERIVATIVES OF PYRROLOPYRIMIDINE AND PURINE
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
ES2654160T3 (en) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anti-HMW-MAA IgE antibodies
CA2856149A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
ES2668044T3 (en) 2012-02-22 2018-05-16 The Regents Of The University Of Colorado, A Body Corporate Bouvardine derivatives and therapeutic uses thereof
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
ES2856848T3 (en) 2012-03-30 2021-09-28 Rhizen Pharmaceuticals Ag New 3,5-disubstituted-3H-imidazo [4,5-B] biridine and 3,5-disubstituida-3H- [1,2,3] triazolo [4,5-B] pyridine compounds as protein kinase modulators C-MET
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HUE043552T2 (en) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
HK1211208A1 (en) 2012-08-22 2016-05-20 Immunogen, Inc. Cytotoxic benzodiazepine derivative
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
WO2014062838A2 (en) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
SMT201800561T1 (en) 2012-11-01 2018-11-09 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
HK1219423A1 (en) 2013-02-28 2017-04-07 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
DK2970205T3 (en) 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2 and ALK2 inhibitors and methods for their use
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
TW201524952A (en) 2013-03-15 2015-07-01 Araxes Pharma Llc Covalent inhibitors of KRAS G12C
UY35464A (en) 2013-03-15 2014-10-31 Araxes Pharma Llc KRAS G12C COVALENT INHIBITORS.
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
BR112016006994A8 (en) 2013-10-03 2020-02-27 Kura Oncology Inc erk inhibitors, their uses and pharmaceutical compositions comprising them
NZ718430A (en) 2013-10-04 2021-12-24 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
UA119971C2 (en) 2013-10-10 2019-09-10 Араксіс Фарма Ллк Inhibitors of kras g12c
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
MX2016014143A (en) 2014-04-30 2017-02-15 Pfizer DERIVATIVES OF DIHETEROCICLO LINKED TO CYCLALQUIL.
GEP20197011B (en) 2014-06-19 2019-08-12 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3473271B1 (en) 2014-07-31 2022-07-20 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
JP2017528498A (en) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Inhibitors of KRAS G12C mutant protein
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (en) 2015-04-15 2021-09-28 Araxes Pharma Llc KRAS Condensed Tricyclic Inhibitors and Methods of Using Them
KR20180018507A (en) 2015-04-20 2018-02-21 톨레로 파마수티컬스, 인크. Prediction of Response to Albosis Dip by Mitochondrial Profiling
CA2984421C (en) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
DK3298021T3 (en) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc ALVOCIDIB PRODRUGS THAT HAVE INCREASED BIOTAILABILITY
AR104020A1 (en) 2015-06-04 2017-06-21 Kura Oncology Inc METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
JP7083497B2 (en) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド Combination therapy for the treatment of cancer
MX390633B (en) 2015-09-14 2025-03-04 Infinity Pharmaceuticals Inc SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, MANUFACTURING PROCESS, COMPOSITIONS CONTAINING THEM AND METHODS OF USING THEM.
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC METHOD FOR SCREENING RAS INHIBITORS
KR20180081596A (en) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 Substituted quinazoline compounds comprising substituted heterocyclic groups and methods for their use
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017132617A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
JP6919977B2 (en) 2016-03-16 2021-08-18 クラ オンコロジー，インク． Substituted inhibitors of menin-MLL and how to use them
WO2017161002A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2017201302A1 (en) 2016-05-18 2017-11-23 The University Of Chicago Btk mutation and ibrutinib resistance
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
AU2017321973B2 (en) 2016-09-02 2024-09-05 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CN110312711A (en) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 Heterocyclic compound and its application method as RAS inhibitor
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP6619519B2 (en) 2016-12-19 2019-12-11 トレロ ファーマシューティカルズ， インコーポレイテッド Profiling peptides and methods for sensitivity profiling
US10532042B2 (en) 2016-12-22 2020-01-14 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US20200385364A1 (en) 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11267885B2 (en) 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
CN117298275A (en) 2017-03-24 2023-12-29 库拉肿瘤学公司 Approaches to Treating Hematologic Malignancies and Ewing's Sarcoma
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
TW201906832A (en) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 Compounds for cancer treatment and methods of use thereof
CN110831933A (en) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 Quinazoline derivatives as modulators of mutated KRAS, HRAS or NRAS
MX2019013954A (en) 2017-05-25 2020-08-31 Araxes Pharma Llc KRAS COVALENT INHIBITORS.
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
KR20200051802A (en) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. Anti-folate receptor alpha antibody conjugates and uses thereof
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
JP7424637B2 (en) 2017-11-10 2024-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ASH1L degrading agent and treatment method using the same
AU2018378935B2 (en) 2017-12-07 2024-10-31 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
SG11202009443RA (en) 2018-04-05 2020-10-29 Sumitomo Dainippon Pharma Oncology Inc Axl kinase inhibitors and use of the same
MA52501A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
JP7361722B2 (en) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド KRAS G12C inhibitors and methods of using the same
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
JP7357644B2 (en) 2018-06-11 2023-10-06 アムジエン・インコーポレーテツド KRAS G12C inhibitors for treating cancer
EP3807276B1 (en) 2018-06-12 2025-12-10 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3829580A1 (en) 2018-08-01 2021-06-09 Araxes Pharma LLC Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
AU2019364417A1 (en) 2018-10-24 2021-05-20 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
EP3883565A1 (en) 2018-11-19 2021-09-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
WO2020113071A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc KIF18A inhibitors
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
MA54547A (en) 2018-12-20 2022-03-30 Amgen Inc HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
ES2996960T3 (en) 2018-12-20 2025-02-13 Amgen Inc Heteroaryl amides useful as kif18a inhibitors
JP7662528B2 (en) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド Formulations Containing Heterocyclic Protein Kinase Inhibitors
MX2021010323A (en) 2019-03-01 2021-12-10 Revolution Medicines Inc Bicyclic heterocyclyl compounds and uses thereof.
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
WO2020236947A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
CA3147276A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
MX2022001296A (en) 2019-08-02 2022-02-22 Amgen Inc Kif18a inhibitors.
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
TW202126636A (en) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 Piperidine compounds as menin inhibitors
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
PE20221253A1 (en) 2019-10-28 2022-08-16 Merck Sharp & Dohme SMALL MOLECULE INHIBITORS OF KRAS MUTANT G12C
CN115551500A (en) 2019-10-31 2022-12-30 大鹏药品工业株式会社 4-aminobut-2-enamide derivatives and their salts
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN115873020B (en) 2019-11-04 2025-06-13 锐新医药公司 RAS inhibitors
PE20230249A1 (en) 2019-11-08 2023-02-07 Revolution Medicines Inc BICYCLIC HETEROARYL COMPOUNDS AND THEIR USES
IL292315A (en) 2019-11-14 2022-06-01 Amgen Inc Improved synthesis of a kras g12c inhibitory compound
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
TW202204334A (en) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin inhibitors and methods of use for treating cancer
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
TW202214253A (en) 2020-06-18 2022-04-16 美商銳新醫藥公司 Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022010537A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Gas41 inhibitors and methods of use thereof
US20230255972A1 (en) 2020-07-15 2023-08-17 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
CN116209438A (en) 2020-09-03 2023-06-02 锐新医药公司 Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors
JP7832184B2 (en) 2020-09-15 2026-03-17 レヴォリューション・メディスンズ，インコーポレイテッド Indole derivatives as RAS inhibitors in cancer treatment
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
AR124449A1 (en) 2020-12-22 2023-03-29 Qilu Regor Therapeutics Inc SOS1 INHIBITORS AND USES THEREOF
TW202309022A (en) 2021-04-13 2023-03-01 美商努法倫特公司 Amino-substituted heterocycles for treating cancers with egfr mutations
KR20240004659A (en) 2021-04-30 2024-01-11 셀진 코포레이션 Combination therapy using an anti-BCMA antibody-drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
PE20240088A1 (en) 2021-05-05 2024-01-16 Revolution Medicines Inc RAS INHIBITORS
CN117500811A (en) 2021-05-05 2024-02-02 锐新医药公司 Covalent RAS inhibitors and their uses
AR125787A1 (en) 2021-05-05 2023-08-16 Revolution Medicines Inc RAS INHIBITORS
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2023064058A1 (en) 2021-10-12 2023-04-20 Peloton Therapeutics Inc. Tricyclic sultams and sulfamides as antitumor agents
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US20250188036A1 (en) 2022-03-07 2025-06-12 Amgen Inc. A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
EP4489755A1 (en) 2022-03-08 2025-01-15 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023211812A1 (en) 2022-04-25 2023-11-02 Nested Therapeutics, Inc. Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
IL317476A (en) 2022-06-10 2025-02-01 Revolution Medicines Inc Macrocyclic ras inhibitors
JP2025525445A (en) 2022-06-30 2025-08-05 ストロ バイオファーマ インコーポレーテッド Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of making and using anti-ROR1 antibodies and antibody conjugates
WO2024010925A2 (en) 2022-07-08 2024-01-11 Nested Therapeutics, Inc. Mitogen-activated protein kinase (mek) inhibitors
CR20250141A (en) 2022-10-14 2025-05-26 Black Diamond Therapeutics Inc Cancer treatment methods using isoquinoline or 6-azaquinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
PE20252777A1 (en) 2023-04-07 2025-12-22 Revolution Medicines Inc MACROCYCLIC RAS INHIBITORS
PE20260039A1 (en) 2023-04-07 2026-01-09 Revolution Medicines Inc MACROCYCLIC RAS INHIBITORS
KR20250169290A (en) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Crystalline form of RAS inhibitor, composition containing same and method of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
AU2024262795A1 (en) 2023-04-24 2025-11-13 Nested Therapeutics, Inc. Heterocyclic derivative as mitogen-activated protein kinase (mek) inhibitor
EP4704850A1 (en) 2023-05-04 2026-03-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024327098A1 (en) 2023-08-24 2026-03-12 Taiho Pharmaceutical Co., Ltd. Fixed dose combinations of cedazuridine and azacitidine
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
US12540197B2 (en) 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025090905A1 (en) 2023-10-26 2025-05-01 Nested Therapeutics, Inc. Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025259841A1 (en) 2024-06-13 2025-12-18 Nested Therapeutics, Inc. Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]jmethyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035750A1 (en) 2024-08-05 2026-02-12 Pivot Therapeutics, Inc. Inhibitors of akt and uses thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606046A1 (en) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
PT766664E (en) * 1994-06-22 2000-08-31 British Biotech Pharm METALOPROTEINASE INHIBITORS
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0845987A4 (en) * 1995-08-08 2000-05-24 Fibrogen Inc C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606046A1 (en) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
CO4600003A1 (en) 1998-05-08
HRP970453A2 (en) 1998-08-31
AU711585B2 (en) 1999-10-14
IL128189A0 (en) 1999-11-30
TW397823B (en) 2000-07-11
JP2000501423A (en) 2000-02-08
PL331895A1 (en) 1999-08-16
ID18063A (en) 1998-02-26
CA2264284A1 (en) 1998-02-26
PA8435301A1 (en) 1999-12-27
HN1997000110A (en) 1998-02-26
KR20000068248A (en) 2000-11-25
TR199900387T2 (en) 1999-04-21
IS4958A (en) 1999-01-26
AP9701078A0 (en) 1997-10-31
EA199900139A1 (en) 1999-08-26
US6153609A (en) 2000-11-28
AR009292A1 (en) 2000-04-12
PE99698A1 (en) 1998-12-26
CN1228083A (en) 1999-09-08
EP0922030A1 (en) 1999-06-16
GT199700094A (en) 1999-02-10
NO990821D0 (en) 1999-02-22
BG103191A (en) 1999-11-30
AU3456397A (en) 1998-03-06
BR9711223A (en) 1999-08-17
OA10978A (en) 2001-11-05
TNSN97139A1 (en) 2005-03-15
NO990821L (en) 1999-02-23
MA24307A1 (en) 1998-04-01
SK21499A3 (en) 2000-05-16
WO1998007697A1 (en) 1998-02-26
ZA977561B (en) 1999-02-22

Similar Documents

Publication Publication Date Title
AP733A (en) Arylsulfonylamino hydroxamic acid derivatives.
AP958A (en) Arylsulfonyl hydroxamic acid derivatives.
EP0821671B1 (en) Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
AP826A (en) Arysulfonylamino hydroxamic acid derivatives.
EP0813520B1 (en) Arylsulfonylamino hydroxamic acid derivatives
EP0895988B1 (en) Arylsulfonylamino hydroxamic acid derivatives
WO1998034915A1 (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
US6380219B1 (en) Arylsulfonylamino hydroxamic acid derivatives
US6509337B1 (en) Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6107337A (en) Arylsulfonylamino hydroxamic acid derivatives
MXPA99001808A (en) Arylsulfonylamino hydroxamic acid derivatives
KR100194258B1 (en) Arylsulfonyl Hydroxamic Acid Derivatives
CZ58999A3 (en) Derivatives of arylsulfonylaminohydroxamic acid, pharmaceutical preparation, inhibition method of matrix metalloproteinases or production of tumor necrosis factor and therapeutical method
MXPA99006301A (en) Cyclic sulfone derivatives